경구 고형 제제 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 메커니즘별, 약효별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Oral Solid Dosage CDMO Market Growth & Trends:

The global oral solid dosage CDMO market size is expected to reach USD 63.50 billion by 2030, and grow at a CAGR of 6.49% from 2025 to 2030. The increasing demand for outsourcing oral solid dosage manufacturing among pharmaceutical and biopharmaceutical companies has compelled contract development and manufacturing organizations (CDMO) to expand their manufacturing facilities to support the demand of pharmaceutical companies. These expansions are made across the globe to enhance their oral solid dosage industry penetration. Furthermore, the rising demand for generic drugs is a key factor for the market growth as there are increasing numbers of generics as OSD products.

The growing number of patients suffering from chronic and infectious diseases is key factor driving demand for novel therapeutics, thereby positively influencing overall industry progression. In addition, Booming geriatric population that are highly prone to chronic diseases and high adoption rate of OSD among this population further supporting the demand for OSD. Furthermore, another factor contributing to the market growth is adverse drug reactions to existing drugs, which have increased the demand for novel treatment options.

Ongoing technological advancements in the oral solid dosage CDMO market to enhance manufacturing efficiency, product quality, and regulatory compliance are positively influencing overall market growth potential. Continuous manufacturing assists seamless integration of numerous unit operations leading to streamlined production workflows and increased flexibility in manufacturing oral solid dosage forms. Moreover, innovations in techniques such as chromatography, spectroscopy, mass spectrometry, and dissolution testing enabled CDMOs to meet enhanced precision, sensitivity, & reliability in pharmaceutical analysis. Furthermore, the integration of automation, robotics, & data analytics streamlined analytical workflows, reduced turnaround times, and enhanced data integrity & compliance with regulatory standards such as Good Manufacturing Practices (GMP) & International Council for Harmonization (ICH) guidelines.

Oral Solid Dosage CDMO Market Report Highlights:

• Basd on product, the tablets segment dominated the market in 2024. The high segment growth is driven by increasing investment in research and development activities, technological advancements in manufacturing processes, innovative drug delivery options and the growing need for advanced solutions to cater to high market demand.
• Based on the mechanism, controlled release segment held the largest market share in 2024 attributing to an improved patient compliance, enhanced efficacy & safety, and reduced frequency of administration.
• Based on the drug potency, low potent drugs segment held the largest market share in 2024 owing to ease of development and manufacturing processes, high demand for generic drugs coupled with need for cost effective solutions, high patient population and high penetration among multiple therapeutic areas to cater effective patient outcome.
• Based on end use, medium & small-size companies segment held the majority revenue share, accounting for over 72.34% in 2024. Growth in the segment can be attributed to the increasing number of small- & medium-sized companies outsourcing their production work to CDMOs and CMOs. Medium and small-sized pharmaceutical companies have limited resources and capabilities in formulation development, process optimization, and manufacturing of oral solid dosage forms. Thus, growing customer preference towards CDMOs for the development and manufacturing of oral solid dosage.
• Asia Pacific dominated the oral solid dosage CDMO market with a share of 36.76% in 2024. The outsourcing of pharmaceutical manufacturing to Asian countries, including India and China, has increased due to their lower costs and availability of potential study subjects. This has led to an increase in clinical studies conducted by pharmaceutical companies in the region. Moreover, high availability of raw materials and advanced manufacturing infrastructure will propel regional market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value Chain-Based Sizing & Forecasting (Model 2)
  • 1.7.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.7.4. Bottom-up Approach (Model 4)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. List of Abbreviations
• 1.11. Objectives
  • 1.11.1. Objective 1
  • 1.11.2. Objective 2
  • 1.11.3. Objective 3
  • 1.11.4. Objective 4

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Oral Solid Dosage CDMO Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Technological Advancements in Oral Solid Dosage (OSD) Forms
    • 3.2.1.2. Expansion of Manufacturing Capacity by CMOs & CDMOs for OSD
    • 3.2.1.3. Increasing Demand for Novel Therapies
    • 3.2.1.4. Increasing Demand for One-Stop-Shop CMOs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Strict Approval Criteria by Regulatory Authorities
    • 3.2.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
    • 3.2.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
• 3.3. Technology Landscape
  • 3.3.1. Manufacturing Technology
  • 3.3.2. Encapsulation Technology
  • 3.3.3. Coating Technology
  • 3.3.4. Packaging Technology
  • 3.3.5. Analytical Technology
• 3.4. Pricing Model Analysis
• 3.5. Oral Solid Dosage Contract Manufacturing Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Oral Solid Dosage CDMO Market: Product Movement Analysis
• 4.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Tablets
  • 4.4.1. Tablets Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Compressed Tablets
    • 4.4.2.1. Compressed Tablets Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Orally Disintegrating Tablets (ODT)
    • 4.4.3.1. Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Chewable Tablets
    • 4.4.4.1. Chewable Tablets Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Bi-layer or Tri-layer Tablets
    • 4.4.5.1. Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.6. Sublingual or Buccal Tablets
    • 4.4.6.1. Sublingual or Buccal Tablets Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.7. Others
    • 4.4.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Capsules
  • 4.5.1. Capsules Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Hard Gelatin Capsules
    • 4.5.2.1. Hard Gelatin Capsules Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Soft Gelatin Capsules
    • 4.5.3.1. Soft Gelatin Capsules Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Powder
  • 4.6.1. Powder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Granules
  • 4.7.1. Granules Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
• 5.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
• 5.4. Immediate Release
  • 5.4.1. Immediate Release Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Delayed Release
  • 5.5.1. Delayed Release Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Controlled Release
  • 5.6.1. Controlled Release Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
• 6.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2018 to 2030 (USD Million)
• 6.4. High Potent Drugs
  • 6.4.1. High Potent Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Moderate Potent Drugs
  • 6.5.1. Moderate Potent Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Low Potent Drugs
  • 6.6.1. Low Potent Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Oral Solid Dosage CDMO Market: End Use Movement Analysis
• 7.3. Global Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Large Size Companies
  • 7.4.1. Large Size Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Medium & Small Size Companies
  • 7.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Oral Solid Dosage CDMO Market: Regional Estimates & Trend Analysis, by Product, by Mechanism, by Drug Potency, by End Use

• 8.1. Regional Dashboard
• 8.2. Oral Solid Dosage CDMO Market: Regional Movement Analysis
• 8.3. North America
  • 8.3.1. North America Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Middle East & Africa
  • 8.7.1. Middle East & Africa Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Oral Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Company Market Share/Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Lonza
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Thermo Fisher Scientific Inc.
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Cambrex Corporation
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Catalent Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Siegrfried Holding AG
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Recipharm AB
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. CordenPharma International
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Boehringer Ingelheim
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Piramal Pharma Solutions
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Aenova Group
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Almac Group
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product/Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Jubilant Pharmova Limited
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product/Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Delpharm
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Product/Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. AbbVie Contract Manufacturing
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Product/Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Next Pharma AB
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Product/Service Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. Rubicon Research Pvt. Ltd.
    • 9.3.16.1. Company Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Product/Service Benchmarking
    • 9.3.16.4. Strategic Initiatives
  • 9.3.17. Quotient Sciences
    • 9.3.17.1. Company Overview
    • 9.3.17.2. Financial Performance
    • 9.3.17.3. Product/Service Benchmarking
    • 9.3.17.4. Strategic Initiatives
  • 9.3.18. Almac Group
    • 9.3.18.1. Company Overview
    • 9.3.18.2. Financial Performance
    • 9.3.18.3. Product/Service Benchmarking
    • 9.3.18.4. Strategic Initiatives
  • 9.3.19. SPI Pharma
    • 9.3.19.1. Company Overview
    • 9.3.19.2. Financial Performance
    • 9.3.19.3. Product/Service Benchmarking
    • 9.3.19.4. Strategic Initiatives
  • 9.3.20. DPT Laboratories Ltd.
    • 9.3.20.1. Company Overview
    • 9.3.20.2. Financial Performance
    • 9.3.20.3. Product/Service Benchmarking
    • 9.3.20.4. Strategic Initiatives
  • 9.3.21. Alcami Corporation
    • 9.3.21.1. Company Overview
    • 9.3.21.2. Financial Performance
    • 9.3.21.3. Product/Service Benchmarking
    • 9.3.21.4. Strategic Initiatives